Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The pharmacological manipulation of liver X receptors (LXRs) has been an attractive therapeutic strategy for atherosclerosis treatment as they control reverse cholesterol transport and inflammatory response. This study presents the development and efficacy of nanoparticles (NPs) incorporating the synthetic LXR agonist GW3965 (GW) in targeting atherosclerotic lesions. Collagen IV (Col IV) targeting ligands are employed to functionalize the NPs to improve targeting to the atherosclerotic plaque, and formulation parameters such as the length of the polyethylene glycol (PEG) coating molecules are systematically optimized. In vitro studies indicate that the GW‐encapsulated NPs upregulate the LXR target genes and downregulate proinflammatory mediator in macrophages. The Col IV‐targeted NPs encapsulating GW (Col IV–GW–NPs) successfully reaches atherosclerotic lesions when administered for 5 weeks to mice with preexisting lesions, substantially reducing macrophage content (≈30%) compared to the PBS group, which is with greater efficacy versus nontargeting NPs encapsulating GW (GW–NPs) (≈18%). In addition, mice administered the Col IV–GW–NPs do not demonstrate increased hepatic lipid biosynthesis or hyperlipidemia during the treatment period, unlike mice injected with the free GW. These findings suggest a new form of LXR‐based therapeutics capable of enhanced delivery of the LXR agonist to atherosclerotic lesions without altering hepatic lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol, inflammation and innate immunity.
Tall, A. R., & Yvan-Charvet, L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3793 · Cited by 1,479
Ito, A., Hong, C., Rong, X., Zhu, X., Tarling, E. J., Hedde, P. N., Gratton, E., Parks, J., & Tontonoz, P. (2015) · eLife · doi:10.7554/elife.08009 · Cited by 281
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7000 · Cited by 164
Cited by
Macrophages in Atherosclerosis Regression
Barrett, T. J. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312802 · Cited by 628
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518
Self-citationTao, W., Yurdagul, A., Kong, N., Li, W., Wang, X., Doran, A. C., Feng, C., Wang, J., Islam, M. A., Farokhzad, O. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1063 · Cited by 255
Self-citationAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
Shin, M., Jin, Y., Park, J., Mun, D., Kim, S. R., Payne, S. M., Kim, K. H., & Kim, Y. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00842 · Cited by 26
Metadata
- Authors
- Yu, M., Amengual, J., Menon, A., Kamaly, N., Zhou, F., Xu, X., Saw, P. E., Lee, S., Si, K., Ortega, C. A., Choi, W. I., Lee, I., Bdour, Y., Shi, J., Mahmoudi, M., Jon, S., Fisher, E. A., & Farokhzad, O. C.
- Venue
- Advanced Healthcare Materials
- Publisher
- Wiley
- Published
- 2017-07-21
- Volume
- 6
- Issue
- 20
- ISSN
- 2192-2640 (ISSN-L)
- 2192-2659
- OpenAlex
- W2737124267
- Cited by
- 83
- References
- 3
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.